Gastroenterologist & hepatologist, Leiden University Medical Center
17th May 2022
Date: May 17, 2022 (Tuesday)
Time: New York 10:00 | London 15:00 | Paris 16:00 | Singapore 22:00 | Tokyo 23:00 | Sydney 00:00 (18th May)
Duration: 90 minutes
Event structure: 3 x 30-minute sessions consisting of a 20-minute presentation + a 10-minute discussion
Registration fee: Complimentary access
Webinar on-demand: Available to view until 1st June 2022 (registration is required)
Dr Manuel Castro Cabezas will chair this webinar in a series of two on the topic: Going beyond the liver in NAFLD/NASH: the hepatologist’s/endocrinologist’s perspective
This webinar series consisting of three presentations with interactive discussions will cover the following topics:
• What is NAFLD/NASH? (Maarten Tushuizen, Leiden University Medical Center)
– Definition & disease spectrum
• Managing patients with diabetes & NAFLD/NASH: the diabetologist’s perspective (Onno Holleboom, Amsterdam University Medical Center)
– NAFLD/NASH & T2DM
– CV drugs in patients with NAFLD/NASH
• Managing NAFLD/NASH: the hepatologist’s perspective (Christophe Moreno, CUB Hôpital Erasme)
– Treatment strategies
This webinar can be followed as the complete series of 3 x 30 minutes sessions but participants are also encouraged to pick and choose the specific topics appealing to their clinical practice or field of interest.
PRESENTERS AND MODERATOR:
Internist, faculty member & Principal Investigator – Amsterdam University Medical Center
Dr. Maarten Tushuizen – Gastroenterologist & hepatologist, Leiden University Medical Center
Dr. Maarten Tushuizen is a gastroenterologist & hepatologist at the Leiden University Medical Center. His research focusses on NAFLD/NASH, principally development of clinical care paths including diagnostics, surveillance and treatment. Furthermore, his interests are the various aspects (including prevention) of NAFLD/NASH before and after liver transplantation, including posttransplantation diabetes mellitus, hepatocellular carcinoma and cardiovascular disease risk.
Dr. Onno Holleboom, MD PhD – Internist, faculty member & Principal Investigator, Amsterdam University Medical Center
Dr. Onno Holleboom MD PhD is an internist registered in Vascular Medicine and Endocrinology, faculty member of the Department of Vascular Medicine and Principal Investigator at Amsterdam UMC. He initiated a multidisciplinary outpatient clinic for NAFLD together with hepatology and including clinical trials. Within the NAFLD-NL consortium and supported by the MLDS foundation, he aims to develop care paths for NAFLD together with LUMC and Radboud MC. Together with prof. Max Nieuwdorp, he runs a research group with 6 PhD candidates focussing on genetic and gut microbial drivers of NAFLD in three cohort studies, as well as more fundamental work on lipid droplet and inflammatory pathways. He has published 60 peer-reviewed articles, including in Circulation and Cell Metabolism and received various prestigious grants, a.o. from The Netherlands Organization for Scientific Research and the Amsterdam UMC Fellowship.
Prof. Christophe Moreno – Professor of Hepatology and Clinical Director, CUB Hôpital Erasme
Prof. Christophe Moreno is Professor of Hepatology and Clinical Director of the Liver Unit in the Department of Gastroenterology, Hepatopancreatology and Digestive Oncology in CUB Hôpital Erasme since 2012. He completed his medical training in the Faculty of Medicine of the Université Libre de Bruxelles and achieved his PhD in the Laboratory of Experimental Gastroenterology (Université Libre de Bruxelles) in 2007. He was president of the Belgian Association for the study of the Liver (2017-2018), member of European Association for the Study of the Liver and the American Association for the Study of Liver disease. He was Associate Editor for Journal of Hepatology (2014-2019) and is Associate Editor for UEG Journal since 2019. Christophe Moreno has published more than 120 articles in prominent journals including the New England Journal of Medicine, JAMA, Gastroenterology, Hepatology and Journal of Hepatology. His main research interests are alcohol-related liver diseases, complications of cirrhosis, and non alcoholic fatty liver disease.
Dr. Manuel Castro Cabezas – Internist-endocrinologist/vascular specialist, Julius Clinical
Dr. Manuel Castro Cabezas is a practicing internist-endocrinologist/vascular specialist. He joined Julius Clinical as Scientific Officer in September 2019. At present he is senior consultant Internal Medicine, Endocrinology, Diabetes and Vascular Medicine at the Franciscus Gasthuis & Vlietland in Rotterdam. Dr Castro Cabezas is scientific officer at Julius Clinical Zeist and associate professor in Medicine at Erasmus MC Rotterdam. He has published over 200 papers in peer reviewed journals dealing with metabolic syndrome, hyperlipemia, diabetes, insulin resistance, obesity, familial combined hyperlipidemia, HIV lipodystrophy and free fatty acid metabolism.
AwareNASH (https://awarenash.eu/) is a research and educational project with the objective to educate clinicians managing patients with NAFLD and NASH on the importance of prompt diagnosis (especially in the case of NASH), along with the relationship of NAFLD/NASH to metabolic disease and CVD.
The Scientific Committee consists of multi-disciplinary experts based in prestigious European University Hospitals. The project is funded by an independent educational grant provided by Pfizer.
With over a decade of experience in hosting life science events, Global Engage is your ideal partner to either devise an agenda for you or work with you and your speakers to promote the online event to our extensive databases.
For further details please contact
Telephone +44 (0) 7538 368 764 or
email [email protected]
Telephone: +603 2117 5193 or
email [email protected]